← Back to all posts
🌟

CRISPR makes prostate cancer vulnerable to immunotherapy

Prostate cancer has been a tough nut to crack when it comes to immunotherapy, but researchers have found a way to make these tumors more susceptible to immune attacks. By using a CRISPR-based tool to modify RNA in cancer cells, they’ve made the tumors more visible to T cells, which are crucial for fighting cancer. This exciting development could enhance the effectiveness of existing immunotherapies, potentially changing the game for patients. It's a monumental step forward in cancer treatment that could lead to better outcomes without the harsh side effects of traditional therapies.
Read the original article ↗
Share